Biomarkers for Neurodegenerative Disorders

Sanna-Kaisa Herukka
Research Fellow

University of Eastern Finland
Institute of Clinical Medicine / Neurology
P.O.Box 1627 (Yliopistonranta 1C)
FI-70211 Kuopio
Finland

+358-(0)40-548 6247
Fax +358-(0)17-162 048
sanna-kaisa.herukka (at) uef.fi

 

ACADEMIC DEGREES

  • MD, 2011
  • PhD (Neurosciences), 2009
  • MSc (Applied biotechnology), 2008

PROFESSIONAL EXPERIENCE

  • Graduate Student, Dept of Neuroscience and Neurology, University of Kuopio 2002- 2007
  • Researcher, Dept of Neurology, University of Kuopio, 2007 –

MAJOR RESEARCH INTERESTS 

  • Biological markers for neurodegenerative disease, particularly Alzheimer's disease
  • Mild cognitive impairment and early Alzheimer's disease

PhD Students

  • Fanni Haapalinna, BM
  • Olli Jääskeläinen, MSc
  • Aku Kaipainen, BM
  • Mikko Moisalo, BM
  • Eero Poukka, BM

Publications in peer-reviewed international journals

The CSF AD profile: easily said, but what do we mean? Floor Duits, Charlotte Teunissen, Femke Bouwman, Pieter Jelle Visser, Niklas Mattsson, Henrik Zetterberg, Kaj Blennow, Oskar Hansson, Lennart Minthon, Niels Andreasen, Jan Marcusson, Anders Wallin, Marcel Olde Rikkert, Magda Tsolaki, Lucilla Parnetti, Sanna-Kaisa Herukka, Harald Hampel, Mony De Leon, Johannes Schröder, Dag Aarsland, Marinus Blankenstein, Philip Scheltens, Wiesje van der Flier. Alzheimers Dement. In press.
 
CSF biomarkers for the differential diagnosis of Alzheimer's disease. A large-scale international multi-center study. Michael Ewers, Niklas Mattsson, Lennart Minthon, Jose L Molinuevo, Anna Antonell, Julius Popp, Frank Jessen, Sanna-Kaisa Herukka, Hilkka Soininen, Walter Maetzler, Thomas Leyhe, Miyako Taniguchi, Katharina Buerger, Katsuya Urakami, Simone Lista, Bruno Dubois, Kaj Blennow, Harald Hampel. Alzheimers Dement. In press.
 
Prevalence and prognosis of prodromal Alzheimer's disease: a pooled analysis of longitudinal cohort studies. Stephanie Vos, Frans Verhey, Lutz Frölich, Johannes Kornhuber, Jens Wiltfang, Wolfgang Maier, Oliver Peters, Eckart Rüther, Flavio Nobili, Silvia Morbelli, Giovanni Frisoni, Alexander Drzerzga, Mira Didic, Bart van Berckel, Andy Simmons, Hilkka Soininen, Iwona Kloszewska, Patrizia Mecocci, Magda Zolaki, Bruno Vellas, Simon Lovestone, Cristina Muscio, Sanna-Kaisa Herukka, Eric Salmon, Christine Bastin, Anders Wallin, Arto Nordlund, Alexandre de Mendonca, Dina Silva, Isabel Santana, Raquel Lemos, Sebastiaan Engelborghs, Stefan Van der Mussele, the Alzheimer's Disease Neuroimaging Initiative, Yvonne Freund-Levi, Asa Wallin, Harald Hampel, Wiesje van der Flier, Philip Scheltens, Pieter Jelle Visser. Brain. In press.
 
Use of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's and Parkinson's disease. Alberto Lleó, Enrica Cavedo, Lucilla Parnetti, HugoVanderstichele, Sanna-Kaisa Herukka, Niels Andreasen, Roberta Ghidoni, Piotr Lewczuk, Andreas Jeromin, Magda Tsolaki, Barbara Mroczko, Pieter J Visser, Isabel Santana, Per Svenningsson, Kaj Blennow, Dag Aarsland, José Luis Molinuevo, Henrik Zetterberg, Brit Mollenhauer. Nat Rev Neurol, 2015;11(1):41-55.

CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4. Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, Helisalmi S, Ewers M, Hampel H, Wallin A, Minthon L, Hardy J, Blennow K, Zetterberg H. Mol Psychiatry. 2013 Feb 19.

Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease. Zetterberg H, Lunn MP, Herukka SK. Biomark Med. 2012 Aug;6(4):371-6.

Age and diagnostic performance of Alzheimer disease CSF biomarkers. Mattsson N, Rosén E, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek MM, Olde Rikkert M, Tsolaki M, Mulugeta E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Wallin A, Eriksdotter-Jönhagen M, Minthon L, Winblad B, Blennow K, Zetterberg H. Neurology. 2012 Feb 14;78(7):468-76.

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Seppälä TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, Pyykkö OT, Helisalmi S, Alafuzoff I, Hiltunen M, Jääskeläinen JE, Rinne J, Soininen H, Leinonen V, Herukka SK. Neurology. 2012 May 15;78(20):1568-75.

Metabolome in progression to Alzheimer's disease. Orešič M, Hyötyläinen T, Herukka SK, Sysi-Aho M, Mattila I, Seppänan-Laakso T, Julkunen V, Gopalacharyulu PV, Hallikainen M, Koikkalainen J, Kivipelto M, Helisalmi S, Lötjönen J, Soininen H. Transl Psychiatry. 2011 Dec 13;1:e57.

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.
Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K. Alzheimers Dement. 2011 Jul;7(4):386-395.e6.

Longitudinal changes of CSF biomarkers in Alzheimer's disease. Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK. J Alzheimer's Dis. 2011;25(4):583-94. 

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Niklas Mattsson, Henrik Zetterberg, Elisabet Londos, Niels Andreasen, Alessia Lanari, Michael Jonsson, Sanna-Kaisa Herukka, Wiesje M van der Flier, Michael Evers, Kenneth Rich, Elmar Kaiser, Erik Rosén, Dag Aarsland, Pieter Jelle-Visser, Johannes Schröder, Jan Marcusson, Mony de Leon, Harald Hampel, Philip Scheltens, Tuula Pirttilä, Anders Wallin, Lucilla Parnetti, Maria Eriksdotter, Jönhagen, Lennart Minthon, Bengt Winblad, Kaj Blennow. JAMA 2009;302(4):385-93. 

CSF beta-amyloid and Tau proteins are markers of Alzheimer-type pathology in the brain. Tero Tapiola, Irina Alafuzoff, Sanna-Kaisa Herukka, Laura Parkkinen, Päivi Hartikainen, Hilkka Soininen, Tuula Pirttilä. Arch Neurol, 2009;66(3):382-9.

PET amyloid ligand [11C]PIB uptake and CSF Abeta in MCI. Jaana Koivunen,  Tuula Pirttilä,  Nina Kemppainen, Sargo Aalto,  Sanna-Kaisa Herukka, Anne Hämäläinen, Tuomo Hänninen, Merja Hallikainen, Kjell Någren, Juha O. Rinne, Hilkka Soininen. Dement Geriatr Cogn Disord 2008;26(4):378-383.

Cerebrospinal fluid Aß42, Tau and phosphorylated Tau correlate with hippocampal atrophy. Sanna-Kaisa Herukka, Corina Pennanen, Hilkka Soininen, Tuula Pirttilä. J Alzheimers Dis 2008;14(1):51-7.

The association study between DHCR24 polymorphisms and Alzheimer's disease. Riikka Lämsä, Seppo Helisalmi, Mikko Hiltunen, Sanna-Kaisa Herukka, Tero Tapiola, Tuula Pirttilä, Saila Vepsäläinen, Hilkka Soininen. Am J Genet B Neuropsychiatr Genet 2007;144B(7):906-10.

Genetic study evaluating LDLR polymorphisms and Alzheimer's disease. Riikka Lämsä, Seppo Helisalmi, Sanna-Kaisa Herukka, Tero Tapiola, Tuula Pirttilä, Saila Vepsäläinen, Mikko Hiltunen, Hilkka Soininen. Neurobiol Aging 2008;29(6):848-55.

CSF Aß42, Tau and phosphorylated Tau, APOE ε4 allele and MCI type in progressive MCI. Sanna-Kaisa Herukka, Seppo Helisalmi, Merja Hallikainen, Susanna Tervo, Hilkka Soininen, Tuula Pirttilä. Neurobiol Aging 2007;28(4):507-14.

CSF Aß42 and Tau or phosphorylated Tau and prediction of progressive mild cognitive impairment. Sanna-Kaisa Herukka, Merja Hallikainen, Hilkka Soininen, Tuula Pirttilä. Neurology 2005;64(7):1294-7.